A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 52 Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease